For investors in 2017, the "high-risk, high-reward" segment of the market was defined by a strong rebound in energy, explosive breakthroughs in biotechnology, and the rising dominance of high-growth technology. While the broader market saw a lack of volatility, with the S&P 500 rising roughly 20% and the Nasdaq nearly 30%, these specific sectors offered triple-digit gains for those willing to stomach higher volatility.
: Despite a "chaotic news cycle," markets remained remarkably steady, allowing growth premiums to outperform value premiums significantly. high risk stocks to buy 2017
: A top performer in the S&P 500 with a 132% gain . High risk stemmed from a major corporate overhaul, where the company shed clean energy assets and cut costs under pressure from activist investors. For investors in 2017, the "high-risk, high-reward" segment
: Nine of the top ten performing stocks of the year were in the biotech sector. Companies like Vertex Pharmaceuticals (VRTX) (up 97%) and Dynavax Technologies (DVAX) (up 373%) succeeded based on FDA approvals and breakthrough trial data. : A top performer in the S&P 500 with a 132% gain